Editorial Summary The arrival of GLP-1 anti-obesity drugs at scale in India has reignited debate on the medicalisation of lifestyle conditions. With 47% out-of-pocket health expenditure and weak structural prevention (food labelling, sugar taxation, active transport), pharmacological solutions risk substituting for, rather than complementing, cheaper public-health measures. A regulatory framework that funds prevention first and regulates pharmaceutical pricing second is essential.
The Backdrop
GLP-1 receptor agonists: a class of drugs originally developed for type-2 diabetes, have emerged as blockbuster anti-obesity treatments over the past 3-5 years globally. Brand names familiar now in Indian metros:
- Ozempic / Wegovy (semaglutide; Novo Nordisk)
- Mounjaro / Zepbound (tirzepatide; Eli Lilly)
- Rybelsus (oral semaglutide)
- Indian biosimilars from Biocon, Dr Reddy’s, Lupin, under development; expected market entry 2026-27
These drugs produce 15-22% body weight loss over 6-12 months, clinical trial evidence is robust. But they are taken indefinitely (effect reverses on discontinuation), priced at ₹20,000-50,000/month in India, and carry significant side-effects.
The Medicalisation Thesis
Medicalisation is the process by which non-medical conditions (social, behavioural, environmental) are defined as medical problems requiring medical intervention. Applied to obesity:
- Pre-medicalisation framing: Obesity as a lifestyle condition addressable through diet, exercise, and environmental design (walkable cities, affordable fresh food, reduced UPF consumption)
- Medicalisation framing: Obesity as a chronic metabolic disease requiring lifelong pharmacological management
Both framings have partial truth, some obesity cases have genuine endocrine/metabolic roots; but most of India’s rising BMI is driven by food system and physical environment changes, not medical pathology.
The Concerns
1. Equity
- GLP-1 monthly cost (₹20,000-50,000) exceeds median Indian household monthly income
- Creates a two-tier health landscape
- Urban elite access, rural access near-zero
2. Sustainability
- Indefinite medication → lifelong drug dependence
- Reversal on discontinuation → unsuitable for periodic use
- Opportunity cost: resources spent on drugs unavailable for prevention
3. Side-effects and Secondary Pharma
- Sarcopenia (muscle loss), requires BCAA supplementation
- Gastrointestinal (nausea, vomiting, constipation), requires acid suppressants
- Gallbladder inflammation, requires cholesterol-lowering agents in some cases
- Psychiatric, depression, anxiety reported; SSRIs sometimes follow
Each side-effect creates a new market. The total lifetime pharmaceutical spend on managing GLP-1 therapy can be 2-3x the drug cost alone.
4. Regulatory Gaps
- FSSAI front-of-pack labelling: draft since 2019; still not mandatory
- Sugar tax: under discussion; no national implementation
- UPF (ultra-processed food) taxation: none
- Direct-to-consumer pharmaceutical advertising: CDSCO oversight weak
- Aggressive marketing to upper-middle-class urban consumers in tier-1 metros
The Cheaper Alternative: Public Health
International evidence strongly supports structural interventions:
| Intervention | Cost-Effectiveness | Evidence Base |
|---|---|---|
| Sugar-sweetened beverage tax | Very high (Mexico 2014, UK 2018) | 8-12% consumption reduction; Type-2 diabetes incidence decline |
| Front-of-pack labelling | Moderate-high | Chile 2016, warning labels on UPF caused 25% reduction in sugar purchases |
| Active transport infrastructure | Very high | Bogotá, Copenhagen; significant reduction in population BMI |
| School meal reform | High | UK’s Jamie Oliver reforms; Kerala’s mid-day meal fruit inclusion |
| Workplace wellness | Moderate | Mixed evidence; infrastructure-dependent |
| GLP-1 drugs | Individually high; population low | Requires 20-30% of adult population to shift outcomes |
India’s policy focus remains skewed toward treatment over prevention.
Ethical Dimensions
Autonomy vs Paternalism
- Individual right to access approved medications, legitimate
- But state has a duty to ensure structural conditions favour health
- Balance: regulate pharmaceutical pricing + advertising, don’t restrict access
Equity
- Treatments available to wealthy should not normalise a two-tier health landscape
- Requires DPCO inclusion of GLP-1 drugs once patent-expires
- India’s compulsory licensing regime (Section 84 Patents Act 1970) provides tool, used for Bayer’s Nexavar in 2012
Public-Health Ethics
- Mission LiFE’s environmental framing, sustainable diets, physical activity, aligns with structural prevention
- But requires parallel regulatory muscle, sugar/UPF taxation, food labelling, active-transport infrastructure
The Institutional Architecture Needed
- CDSCO strengthening: Direct-to-consumer advertising rules, post-market surveillance
- NPPA expansion: Include lifestyle drugs in price control; cap innovator-drug prices once critical mass reached
- FSSAI reform: Mandate front-of-pack warning labels (similar to Chile model)
- Finance Ministry action: Sugar and UPF taxation (GST Council)
- MoHFW focus: National Action Plan on Obesity Prevention (currently absent)
- Ministry of Housing & Urban Affairs: Active-transport infrastructure in AMRUT 2.0 and Smart Cities
Coordinated, this would address the root causes (food system, physical environment) rather than only the symptoms (individual weight).
UPSC Relevance
| Paper | Angle |
|---|---|
| GS2, Health/Governance | CDSCO, NPPA, FSSAI, NHP 2017, National Health Accounts, PMJAY |
| GS2, Social Justice | Equity in health; OOP expenditure; health impoverishment |
| GS3, S&T | GLP-1 mechanism; biosimilar development; pharmaceutical innovation |
| GS4, Ethics | Medicalisation vs autonomy; pharmaceutical profit vs public health; Mission LiFE |
| Mains Keywords | Medicalisation, GLP-1 agonists, Ozempic/Wegovy/Mounjaro, out-of-pocket expenditure, FSSAI, sugar tax, NPPA, Section 84 Patents Act, Mission LiFE |
The rise of pharmacological solutions for what were once lifestyle, social, or environmental conditions, obesity, anxiety, loneliness, ageing, reflects a structural shift toward commodified healthcare that risks displacing cheaper, more equitable public-health approaches and deepening out-of-pocket expenditure burdens on Indian households.
- Anti-obesity drugs (GLP-1 receptor agonists, Ozempic, Wegovy, Mounjaro) entered the Indian market in 2024-25 with prices of ₹20,000-₹50,000/month, beyond reach of most Indians, yet have become the cultural reference point for obesity management.
- Side-effect management is creating secondary pharmaceutical markets: GLP-1 users experience sarcopenia (muscle loss) requiring branched-chain amino acid supplementation; gastrointestinal issues requiring acid suppressants. Each condition creates a new revenue stream.
- The 47% out-of-pocket health expenditure share (National Health Accounts 2023) makes pharmaceutical cost-escalation a direct driver of ‘health impoverishment’, NFHS-5 estimates ~35 million Indians pushed into poverty annually by health expenses.
- India’s Food Safety and Standards Authority (FSSAI) has reduced enforcement of front-of-pack labelling reform; regulatory clarity on sugar taxation remains absent, creating conditions where prevention is weak and treatment is commercialised.
Pharmacological interventions are legitimate medical tools that address real pathologies. Opposing their availability on ‘medicalisation’ grounds risks elite paternalism, denying access to treatments widely available globally.
Public-health prevention and pharmaceutical treatment should coexist, not compete.
Four-pillar regulation: (1) Public funding of structural prevention, front-of-pack labelling, sugar/UPF tax, active-transport urban planning; (2) Price regulation of lifestyle drugs (Drug Price Control Orders + National Pharmaceutical Pricing Authority); (3) Stricter CDSCO oversight on direct-to-consumer advertising; (4) Conflict-of-interest rules for clinician prescribing patterns; and public awareness that lifestyle drugs are complement, not substitute, to public-health infrastructure.
The 'medicalisation' of lifestyle conditions, via anti-obesity drugs, anti-ageing therapies, and pharmacological solutions for social problems, has intensified in India. Analyse the ethical, public-health, and economic implications, and suggest a regulatory framework that balances innovation with over-medicalisation concerns. (250 words)
India’s health expenditure is increasingly dominated by pharmacological spending, on drugs, diagnostics, and devices, while structural public-health infrastructure (sanitation, urban planning, food regulation, active transport) receives far less priority. The arrival of anti-obesity GLP-1 drugs at scale marks a further turning point in this ‘medicalisation’ of lifestyle conditions, raising ethical, public-health, and distributional questions.
The shift has four dimensions. First, commodification of lifestyle: GLP-1 agonists (semaglutide, Ozempic/Wegovy; tirzepatide, Mounjaro) priced at ₹20,000-50,000/month have become the cultural reference for obesity management, but are beyond reach of 90%+ of Indians. This creates a two-tier health system where wealth determines access to pharmaceutical solutions. Second, side-effect industry: GLP-1 users experience sarcopenia (muscle loss), gastrointestinal issues, gallbladder complications, each requiring secondary drugs, creating escalating pharmaceutical dependence.
Branched-chain amino acids, proton pump inhibitors, and urso-deoxycholic acid have seen prescription surges alongside GLP-1 rollout. Third, out-of-pocket impact: India’s 47% OOP health expenditure share (National Health Accounts 2023) already pushes ~35 million into poverty annually (NFHS-5). Pharmaceutical cost-escalation amplifies this. Fourth, regulatory vacuum: FSSAI’s front-of-pack labelling draft has stalled; sugar/UPF taxation debate is unresolved; CDSCO direct-to-consumer advertising oversight is weak.
The net effect: weak prevention, commercialised treatment. Ethically, this raises Article 21 questions, does the right to health include a right to affordable structural prevention, not just theoretical access to expensive drugs?
Regulating medicalisation requires four parallel reforms: strengthening structural public-health (FSSAI front-of-pack labelling, sugar/UPF taxation, active-transport urban planning); pricing regulation of lifestyle drugs via DPCO/NPPA; CDSCO oversight on direct-to-consumer advertising; and conflict-of-interest norms for prescribers. The goal is not to oppose GLP-1 access, which is a legitimate medical tool, but to ensure it does not become the default where prevention, education, and environmental redesign should be primary.
A public health system funds water, food, and movement before it funds molecules.
Interview Angle
"India's out-of-pocket health expenditure remains ~47% of total health spending. In this context, is the arrival of anti-obesity drugs (GLP-1 agonists like Ozempic/Wegovy) at scale a public-health advance, or a commercial shift that medicalises problems solvable by food policy and physical infrastructure?"
Cite this page: The Alarming Rise of Medicalisation in India: From Public Health to Pharmaceutical Dependence — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
